Evoke Wealth LLC Has $5.76 Million Stock Position in Eli Lilly and Company (NYSE:LLY)

Evoke Wealth LLC lifted its position in Eli Lilly and Company (NYSE:LLY) by 2.9% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 7,466 shares of the company’s stock after acquiring an additional 211 shares during the period. Evoke Wealth LLC’s holdings in Eli Lilly and Company were worth $5,764,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the company. Horizon Investments LLC raised its position in Eli Lilly and Company by 64.3% during the fourth quarter. Horizon Investments LLC now owns 8,932 shares of the company’s stock worth $6,896,000 after acquiring an additional 3,497 shares in the last quarter. Thrivent Financial for Lutherans boosted its position in shares of Eli Lilly and Company by 9.5% in the fourth quarter. Thrivent Financial for Lutherans now owns 468,736 shares of the company’s stock valued at $362,875,000 after acquiring an additional 40,776 shares during the period. PDS Planning Inc increased its stake in Eli Lilly and Company by 1.3% during the 4th quarter. PDS Planning Inc now owns 5,926 shares of the company’s stock worth $4,575,000 after acquiring an additional 74 shares during the period. Mystic Asset Management Inc. raised its stake in Eli Lilly and Company by 2.0% in the fourth quarter. Mystic Asset Management Inc. now owns 2,618 shares of the company’s stock valued at $2,021,000 after purchasing an additional 51 shares in the last quarter. Finally, RD Lewis Holdings Inc. acquired a new stake in shares of Eli Lilly and Company during the 4th quarter worth approximately $1,965,000. 82.53% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of analysts have weighed in on LLY shares. Berenberg Bank set a $970.00 target price on shares of Eli Lilly and Company in a research report on Thursday, January 16th. Morgan Stanley set a $1,146.00 price target on shares of Eli Lilly and Company in a research report on Thursday, March 6th. Bank of America reissued a “buy” rating and set a $997.00 target price on shares of Eli Lilly and Company in a research note on Tuesday, December 10th. Truist Financial boosted their price target on shares of Eli Lilly and Company from $1,029.00 to $1,038.00 and gave the company a “buy” rating in a research note on Monday, February 3rd. Finally, Citigroup decreased their price target on Eli Lilly and Company from $1,250.00 to $1,190.00 and set a “buy” rating for the company in a report on Tuesday, January 28th. Three investment analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $1,009.72.

Eli Lilly and Company Stock Performance

NYSE:LLY opened at $825.48 on Tuesday. The stock’s 50 day simple moving average is $832.05 and its two-hundred day simple moving average is $841.68. Eli Lilly and Company has a 1 year low of $711.40 and a 1 year high of $972.53. The company has a market cap of $782.70 billion, a price-to-earnings ratio of 70.49, a PEG ratio of 1.40 and a beta of 0.34. The company has a debt-to-equity ratio of 2.00, a current ratio of 1.15 and a quick ratio of 0.97.

Eli Lilly and Company (NYSE:LLY) last issued its earnings results on Thursday, February 6th. The company reported $5.32 EPS for the quarter, missing analysts’ consensus estimates of $5.45 by ($0.13). Eli Lilly and Company had a return on equity of 85.24% and a net margin of 23.51%. As a group, equities analysts anticipate that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company announced that its board has approved a share buyback plan on Monday, December 9th that allows the company to repurchase $15.00 billion in shares. This repurchase authorization allows the company to buy up to 2% of its stock through open market purchases. Stock repurchase plans are often an indication that the company’s management believes its shares are undervalued.

Insider Transactions at Eli Lilly and Company

In related news, CAO Donald A. Zakrowski sold 1,000 shares of Eli Lilly and Company stock in a transaction dated Thursday, March 13th. The stock was sold at an average price of $818.24, for a total value of $818,240.00. Following the completion of the transaction, the chief accounting officer now owns 5,840 shares in the company, valued at $4,778,521.60. The trade was a 14.62 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 0.13% of the company’s stock.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.